Serine protease activity contributes to control of Mycobacterium tuberculosis in hypoxic lung granulomas in mice

Journal of Clinical Investigation

Volumn 120, Issue 9, 2010, Pages 3365-3376

  Reece, Stephen T ^a   Loddenkemper, Christoph ^b,d   Askew, David J ^c   Zedler, Ulrike ^a   Schommer Leitner, Sandra ^a   Stein, Maik ^a   Mir, Fayaz Ahmad ^a   Dorhoi, Anca ^a   Mollenkopf, Hans Joachim ^a   Silverman, Gary A ^c   Kaufmann, Stefan H E ^a  

^a MAX PLANCK INSTITUTE FOR INFECTION BIOLOGY   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CATHEPSIN G; GAMMA INTERFERON; MESSENGER RNA; SERINE PROTEINASE INHIBITOR; SERINE PROTEINASE INHIBITOR B3A; SERINE PROTEINASE INHIBITOR B3B; SERINE PROTEINASE INHIBITOR B3C; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL GROWTH; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; GENE EXPRESSION; HYPOXIA; LUNG GRANULOMA; LUNG TUBERCULOSIS; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN TUBERCULOSIS;

ANIMALS; ANOXIA; CATHEPSIN G; GRANULOMA; LUNG; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYCOBACTERIUM TUBERCULOSIS; NECROSIS; PULMONARY FIBROSIS; SERINE PROTEASES; TUBERCULOSIS, PULMONARY;

EID: 77956353995     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI42796     Document Type: Article

References (59)

1. Saunders BM, Britton WJ. Life and death in the granuloma: immunopathology of tuberculosis. Immunol Cell Biol. 2007;85(2):103-111.
2. Ulrichs T, Kaufmann SH. New insights into the function of granulomas in human tuberculosis. J Pathol. 2006;208(2):261-269.
3. Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis. 2004;38(9):1261-1265.
4. Keane J, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001;345(15):1098-1104.
5. Kaufmann SH, McMichael AJ. Annulling a dangerous liaison: vaccination strategies against AIDS and tuberculosis. Nat Med. 2005;11(4 suppl):S33-S44.
6. Kaplan G, et al. Mycobacterium tuberculosis growth at the cavity surface: a microenvironment with failed immunity. Infect Immun. 2003;71(12):7099-7108.
7. Loring WE, Vandiviere HM. The treated pulmonary lesion and its tubercle bacillus. I. Pathology and pathogenesis. Am J Med Sci. 1956;232(1):20-29.
8. Ghon A. Der primäre Lungenherd bei der Tuberkulose der Kinder. [The Primary Lung Lesion Of Infant Tuberculosis]. Berlin, Germany: Urban and Schwarzenberg; 1912.
9. Dannenberg AM. Pathogenesis of Human Pulmonary Tuberculosis. Washington DC, USA: ASM Press; 2006.
10. Boshoff HI, Barry CE 3rd. Tuberculosis - metabolism and respiration in the absence of growth. Nat Rev Microbiol. 2005;3(1):70-80.
11. Young DB, Perkins MD, Duncan K, Barry CE 3rd. Confronting the scientific obstacles to global control of tuberculosis. J Clin Invest. 2008;118(4):1255- 1265.
12. North RJ, Jung YJ. Immunity to tuberculosis. Annu Rev Immunol. 2004;22:599-623.
13. Aly S, et al. Oxygen status of lung granulomas in Mycobacterium tuberculosis-infected mice. J Pathol. 2006;210(3):298-305.
14. Via LE, et al. Tuberculous granulomas are hypoxic in guinea pigs, rabbits, and nonhuman primates. Infect Immun. 2008;76(6):2333-2340.
15. Marcoval J, Servitje O, Moreno A, Jucgla A, Peyri J. Lupus vulgaris. Clinical, histopathologic, and bacteriologic study of 10 cases. J Am Acad Dermatol. 1992;26(3 pt 2):404-407.
16. Bravo FG, Gotuzzo E. Cutaneous tuberculosis. Clin Dermatol. 2007;25(2):173-180.
17. Chan J, Xing Y, Magliozzo RS, Bloom BR. Killing of virulent Mycobacterium tuberculosis by reactive nitrogen intermediates produced by activated murine macrophages. J Exp Med. 1992;175(4):1111-1122.
18. MacMicking JD, North RJ, LaCourse R, Mudgett JS, Shah SK, Nathan CF. Identification of nitric oxide synthase as a protective locus against tuberculosis. Proc Natl Acad Sci U S A. 1997;94(10):5243-5248.
19. Scanga CA, Mohan VP, Tanaka K, Alland D, Flynn JL, Chan J. The inducible nitric oxide synthase locus confers protection against aerogenic challenge of both clinical and laboratory strains of Mycobacterium tuberculosis in mice. Infect Immun. 2001;69(12):7711-7717.
20. Gonzalez-Juarrero M, Turner OC, Turner J, Marietta P, Brooks JV, Orme IM. Temporal and spatial arrangement of lymphocytes within lung granulomas induced by aerosol infection with Mycobacterium tuberculosis. Infect Immun. 2001;69(3):1722-1728.
21. Jung YJ, LaCourse R, Ryan L, North RJ. Virulent but not avirulent Mycobacterium tuberculosis can evade the growth inhibitory action of a T helper 1-dependent, nitric oxide Synthase 2-independent defense in mice. J Exp Med. 2002;196(7):991-998.
22. de Noronha A, Báfica A, Nogueira L, Barral A, Barral-Netto M. Lung granulomas from Mycobacterium tuberculosis/HIV-1 co-infected patients display decreased in situ TNF production. Pathol Res Pract. 2008;204(3):155-161.
23. Beisiegel M, et al. Combination of host susceptibility and virulence of Mycobacterium tuberculosis determines dual role of nitric oxide in the protection and control of inflammation. J Infect Dis. 2009;199(8):1222-1232.
24. Basaraba RJ. Experimental tuberculosis: the role of comparative pathology in the discovery of improved tuberculosis treatment strategies. Tuberculosis (Edinb). 2008;88(suppl 1):S35-S47.
25. Yan BS, et al. Progression of pulmonary tuberculosis and efficiency of bacillus Calmette-Guerin vaccination are genetically controlled via a common sst1-mediated mechanism of innate immunity. J Immunol. 2007;179(10):6919-6932.
26. Pan H, et al. Ipr1 gene mediates innate immunity to tuberculosis. Nature. 2005;434(7034):767-772.
27. Lin PL, et al. Early events in Mycobacterium tuberculosis infection in cynomolgus macaques. Infect Immun. 2006;74(7):3790-3803.
28. Lin PL, et al. Quantitative comparison of active and latent tuberculosis in the cynomolgus macaque model. Infect Immun. 2009;77(10):4631-4642.
29. Raleigh JA, Chou SC, Bono EL, Thrall DE, Varia MA. Semiquantitative immunohistochemical analysis for hypoxia in human tumors. Int J Radiat Oncol Biol Phys. 2001;49(2):569-574.
30. Raleigh JA, Chou SC, Calkins-Adams DP, Ballenger CA, Novotny DB, Varia MA. A clinical study of hypoxia and metallothionein protein expression in squamous cell carcinomas. Clin Cancer Res. 2000;6(3):855-862.
31. Varia MA, et al. Pimonidazole: a novel hypoxia marker for complementary study of tumor hypoxia and cell proliferation in cervical carcinoma. Gynecol Oncol. 1998;71(2):270-277.
32. Reeves E, et al. Killing activity of neutrophils is mediated through activation of proteases by K+ flux. Nature. 2002;416(6878):291-297.
33. Belaaouaj A, et al. Mice lacking neutrophil elastase reveal impaired host defense against gram negative bacterial sepsis. Nat Med. 1998;4(5):615-618.
34. Pham CT. Neutrophil serine proteases: specific regulators of inflammation. Nat Rev Immunol. 2006;6(7):541-550.
35. Campbell EJ, Silverman EK, Campbell MA. Elastase and cathepsin G of human monocytes. Quantification of cellular content, release in response to stimuli, and heterogeneity in elastase-mediated proteolytic activity. J Immunol. 1989;143(9):2961-2968.
36. Kargi HA, Campbell EJ, Kuhn C 3rd. Elastase and cathepsin G of human monocytes: heterogeneity and subcellular localization to peroxidase-positive granules. J Histochem Cytochem. 1990;38(8):1179-1186.
37. Rivera-Marrero C, Stewart J, Shafer W, Roman J. The down-regulation of cathepsin G in THP-1 monocytes after infection with Mycobacterium tuberculosis is associated with increased intracellular survival of bacilli. Infect Immun. 2004;72(10):5712-5721.
38. Caughey GH. A pulmonary perspective on GASPIDs: granule-associated serine peptidases of immune defense. Curr Respir Med Rev. 2006;2(39):263-277.
39. Robinson MA, Baumgardner JE, Good VP, Otto CM. Physiological and hypoxic O2 tensions rapidly regulate NO production by stimulated macrophages. Am J Physiol Cell Physiol. 2008;294(4):C1079-C1087.
40. Nathan C. Microbiology. An antibiotic mimics immunity. Science. 2008;322(5906):1337-1338.
41. Benarafa C, Priebe GP, Remold-O'Donnell E. The neutrophil serine protease inhibitor serpinb1 preserves lung defense functions in Pseudomonas aeruginosa infection. J Exp Med. 2007;204(8):1901-1909.
42. Moraes TJ, Zurawska JH, Downey GP. Neutrophil granule contents in the pathogenesis of lung injury. Curr Opin Hematol. 2006;13(1):21-27.
43. Taggart CC, Greene CM, Carroll TP, O'Neill SJ, McElvaney NG. Elastolytic proteases: inflammation resolution and dysregulation in chronic infective lung disease. Am J Respir Crit Care Med. 2005;171(10):1070-1076.
44. Luke CJ, et al. An intracellular serpin regulates necrosis by inhibiting the induction and sequelae of lysosomal injury. Cell. 2007;130(6):1108-1119.
45. Silverman GA, et al. Human clade B serpins (ov-serpins) belong to a cohort of evolutionarily dispersed intracellular proteinase inhibitor clades that protect cells from promiscuous proteolysis. Cell Mol Life Sci. 2004;61(3):301-325.
46. Bartuski AJ, Kamachi Y, Schick C, Massa H, Trask BJ, Silverman GA. A murine ortholog of the human serpin SCCA2 maps to chromosome 1 and inhibits chymotrypsin-like serine proteinases. Genomics. 1998;54(2):297-306.
47. Al-Khunaizi M, et al. The serpin SQN-5 is a dual mechanistic-class inhibitor of serine and cysteine proteinases. Biochemistry. 2002;41(9):3189- 3199.
48. Askew DJ, et al. The amplified mouse squamous cell carcinoma antigen gene locus contains a serpin (Serpinb3b) that inhibits both papain-like cysteine and trypsin-like serine proteinases. Genomics. 2004;84(1):166-175.
49. Buitrago-Rey R, Olarte J, Gomez-Marin JE. Evaluation of two inhibitors of invasion: LY311727 [3-(3-acetamide-1-benzyl-2-ethyl-indolyl-5-oxy)propane phosphonic acid] and AEBSF [4-(2-aminoethyl)-benzenesulphonyl fluoride] in acute murine toxoplasmosis. J Antimicrob Chemother. 2002;49(5):871-874.
50. Singh R, et al. PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release. Science. 2008;322(5906):1392-1395.
51. Korkmaz B, Moreau T, Gauthier F. Neutrophil elastase, proteinase 3 and cathepsin G: physicochemical properties, activity and physiopathological functions. Biochimie. 2008;90(2):227-242.
52. Lehrer R, Ganz T. Antimicrobial polypeptides of human neutrophils. Blood. 1990;76(11):2169-2181.
53. Beisiegel M, et al. Combination of host susceptibility and Mycobacterium tuberculosis virulence define gene expression profile in the host. Eur J Immunol. 2009;39(12):3369-3384.
54. Grosset J. Mycobacterium tuberculosis in the extracellular compartment: an underestimated adversary. Antimicrob Agents Chemother. 2003;47(3):833-836.
55. Remold-O'Donnell E, Parent D. Downregulation of neutrophil CD43 by opsonized zymosan. Blood. 1995;85(2):337-342.
56. Andrews B, Bond K, Lehman J, Horn J, Dugan A, Gomez-Cambronero J. Direct inhibition of in vitro PLD activity by 4-(2-aminoethyl)-benzenesulfonyl fluoride. Biochem Biophys Res Commun. 2000;273(1):302-311.
57. Greco E, De Spirito M, Papi M, Fossati M, Auricchio G, Fraziano M. CpG oligodeoxynucleotides induce Ca2+-dependent phospholipase D activity leading to phagolysosome maturation and intracellular mycobacterial growth inhibition in monocytes. Biochem Biophys Res Commun. 2006;347(4):963-969.
58. Dannenberg AM Jr. Liquefaction and cavity formation in pulmonary TB: a simple method in rabbit skin to test inhibitors. Tuberculosis (Edinb). 2009;89(4):243-247.
59. Ellis RC, Zabrowarny LA. Safer staining method for acid fast bacilli. J Clin Pathol. 1993;46(6):559-560.